Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors

The Scientific World Journal

Volumn 2012, Issue , 2012, Pages

  Fendrich, Volker ^a   Maschuw, Katja ^a   Rehm, Johannes ^a   Buchholz, Malte ^a   Holler, Julia P ^b   Slater, Emily P ^a   Bartsch, Detlef K ^a   Waldmann, Jens ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; INSULIN; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; VIRUS T ANTIGEN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS ISLET CELL TUMOR; SOLID TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; C57BL MOUSE; DISEASE COURSE; DRUG EFFECT; GENETICS; KAPLAN MEIER METHOD; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NEUROENDOCRINE TUMOR; PANCREAS ISLET; PANCREAS TUMOR; PATHOLOGY; PROMOTER REGION; RAT; TIME; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR VOLUME; VASCULARIZATION;

MURINAE; MUS; MUS MUSCULUS;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; APOPTOSIS; DISEASE PROGRESSION; FEMALE; INSULIN; ISLETS OF LANGERHANS; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; NIACINAMIDE; PANCREATIC NEOPLASMS; PHENYLUREA COMPOUNDS; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; RATS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

MLCS; MLOWN;

EID: 84872771423     PISSN: 1537744X     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/2012/529151     Document Type: Article

References (36)

1. Öberg K., Eriksson B., Endocrine tumors of the pancreas. Best Practice & Research Clinical Gastroenterology 2005 19 2 753 781 10.1016/j.bpg.2005.06.002 (Pubitemid 41614122)
2. Fendrich V., Langer P., Celik I., Bartsch D. K., Zielke A., Ramaswamy A., Rothmund M., An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Annals of Surgery 2006 244 6 845 851 2-s2.0-33751314527 10.1097/01.sla.0000246951.21252.60
3. Metz D. C., Jensen R. T., Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008 135 5 1469 1492 2-s2.0-55249090388 10.1053/j.gastro.2008.05.047
4. Plockinger U., Wiedenmann B., Biotherapy. Best Practice & Research: Clinical Endocrinology & Metabolism 2007 21 145 162 10.1016/j.beem.2007.01. 002 (Pubitemid 46430284)
5. Rinke A., Müller H. H., Schade-Brittinger C., Klose K. J., Barth P., Wied M., Mayer C., Aminossadati B., Pape U. F., Bläker M., Harder J., Arnold C., Gress T., Arnold R., Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology 2009 27 28 4656 4663 2-s2.0-70350442637 10.1200/JCO.2009.22.8510
6. Raymond E., Dahan L., Raoul J. L., Bang Y. J., Borbath I., Lombard-Bohas C., Valle J., Metrakos P., Smith D., Vinik A., Chen J. S., Hörsch D., Hammel P., Wiedenmann B., Van Cutsem E., Patyna S., Lu D. R., Blanckmeister C., Chao R., Ruszniewski P., Sunitinib Malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine 2011 364 6 501 513 10.1056/NEJMoa1003825
7. Yao J. C., Shah M. H., Ito T., Bohas C. L., Wolin E. M., Van Cutsem E., Hobday T. J., Okusaka T., Capdevila J., De Vries E. G. E., Tomassetti P., Pavel M. E., Hoosen S., Haas T., Lincy J., Lebwohl D., Öberg K., Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 2011 364 6 514 523 2-s2.0-79851500081 10.1056/NEJMoa1009290
8. Hanahan D., Heritable formation of pancreatic β -cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985 315 6015 115 122 2-s2.0-0021888904 (Pubitemid 15064530)
9. Folkman J., Watson K., Ingber D., Hanahan D., Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989 339 6219 58 61 2-s2.0-0024549349 (Pubitemid 19115892)
10. Lopez T., Hanahan D., Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2002 1 4 339 353 2-s2.0-0036559535 10.1016/S1535-6108(02)00055-7 (Pubitemid 41039136)
11. Peri A. K., Wilgenbus P., Dahl U., Semb H., Christofori G., A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998 392 6672 190 193 2-s2.0-0032510494 10.1038/32433 (Pubitemid 28162793)
12. Perl A. K., Dahl U., Wilgenbus P., Cremer H., Semb H., Christofori G., Reduced expression of neural cell adhesion molecule induces metastatic dissemination of pancreatic β tumor cells. Nature Medicine 1999 5 3 286 291 2-s2.0-0032978138 10.1038/6502 (Pubitemid 29124363)
13. Parangi S., O'Reilly M., Christofori G., Holmgren L., Grosfeld J., Folkman J., Hanahan D., Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proceedings of the National Academy of Sciences of the United States of America 1996 93 5 2002 2007 2-s2.0-0030005902 10.1073/pnas.93.5.2002 (Pubitemid 26079871)
14. Inoue M., Hager J. H., Ferrara N., Gerber H. P., Hanahan D., VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis. Cancer Cell 2002 1 2 193 202 2-s2.0-0036491615 10.1016/S1535-6108(02)00031-4 (Pubitemid 41039165)
15. Ferrara N., Vascular endothelial growth factor: molecular and biological aspects. Current Topics in Microbiology and Immunology 1999 237 1 30 (Pubitemid 28554856)
16. Ferrara N., Chen H., Davis-Smyth T., Gerber H. P., Nguyen T. N., Peers D., Chisholm V., Hillan K. J., Schwall R. H., Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature Medicine 1998 4 3 336 340 2-s2.0-0031940839 10.1038/nm0398-336 (Pubitemid 28144094)
17. Carmeliet P., VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nature Medicine 2000 6 10 1102 1103 2-s2.0-0033793881 10.1038/80430
18. Kerbel R. S., Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000 21 3 505 515 2-s2.0-0034092011 (Pubitemid 30137936)
19. Christofori G., Naik P., Hanahan D., Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Molecular Endocrinology 1995 9 12 1760 1770 2-s2.0-0028856096
20. Wilhelm S. M., Adnane L., Newell P., Villanueva A., Llovet J. M., Lynch M., Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics 2008 7 10 3129 3140 2-s2.0-55749088393 10.1158/1535-7163.MCT-08- 0013
21. Fendrich V., Waldmann J., Feldmann G., Schlosser K., König A., Ramaswamy A., Bartsch D. K., Karakas E., Unique expression pattern of the EMT markers Snail, Twist and E-cadherin in benign and malignant parathyroid neoplasia. European Journal of Endocrinology 2009 160 4 695 703 2-s2.0-64549146702 10.1530/EJE-08-0662
22. Fendrich V., Wiese D., Waldmann J., Lauth H. M., Heverhagen A. E., Rehm J., Bartsch D. K., Hedgehog inhibiton with the orally bioavailable Smo antagonist LDE 225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms. Annals of Surgery 2011 254 5 818 823
23. Livak K. J., Schmittgen T. D., Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001 25 4 402 408 2-s2.0-0035710746 10.1006/meth.2001.1262 (Pubitemid 34164012)
24. Bergers G., Javaherian K., Lo K. M., Folkman J., Hanahan D., Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999 284 5415 808 812 2-s2.0-0033617532 10.1126/science.284.5415.808 (Pubitemid 29291347)
25. Bergers G., Brekken R., McMahon G., Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology 2000 2 737 744 10.1038/35036374
26. Christofori G., Naik P., Hanahan D., A second signal supplied by insulin-like growth factor II in oncogene- induced tumorigenesis. Nature 1994 369 6479 414 418 2-s2.0-0028356419 10.1038/369414a0 (Pubitemid 24184057)
27. Porcu P., Ferber A., Pietrzkowski Z., Roberts C. T., Adamo M., LeRoith D., Baserga R., The growth-stimulatory effect of simian virus 40 T antigen requires the interaction of insulinlike growth factor 1 with its receptor. Molecular and Cellular Biology 1992 12 11 5069 5077 2-s2.0-0026744027
28. Petrik J., Pell J. M., Arany E., McDonald T. J., Dean W. L., Reik W., Hill D. J., Overexpression of insulin-like growth factor-II in transgenic mice is associated with pancreatic islet cell hyperplasia. Endocrinology 1999 140 5 2353 2363 2-s2.0-0033323812 (Pubitemid 30636477)
29. Wulbrand U., Wied M., Zöfel P., Göke B., Arnold R., Fehmann H. C., Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. European Journal of Clinical Investigation 1998 28 12 1038 1049 2-s2.0-0032457716 10.1046/j.1365-2362.1998.00397.x (Pubitemid 29050140)
30. Wulbrand U., Remmert G., Zöfel P., Wied M., Arnold R., Fehmann H. C., mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. European Journal of Clinical Investigation 2000 30 8 729 739 2-s2.0-0033852721 10.1046/j.1365-2362.2000.00700.x (Pubitemid 30604075)
31. Bergers G., Brekken R., McMahon G., Vu T. H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D., Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology 2000 2 10 737 744 2-s2.0-0000391746 10.1038/35036374
32. Flaherty K. T., Sorafenib in renal cell carcinoma. Clinical Cancer Research 2007 13 2 747 752 2-s2.0-33846867701 10.1158/1078-0432.CCR-06-2063
33. Compagni A., Wilgenbus P., Impagnatiello M. A., Cotten M., Christofori G., Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Research 2000 60 24 7163 7169 2-s2.0-0034671392 (Pubitemid 32059199)
34. Sobczak I., Galabova-Kovacs G., Sadzak I., Kren A., Christofori G., Baccarini M., B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic β -cell carcinogenesis. Oncogene 2008 27 35 4779 4787 2-s2.0-49749110755 10.1038/onc.2008.128
35. Fujita M., Hayashi I., Yamashina S., Fukamizu A., Itoman M., Majima M., Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2005 26 2 271 279 2-s2.0-13844255555 10.1093/carcin/bgh324 (Pubitemid 40253497)
36. Inoue M., Hager J. H., Ferrara N., Gerber H. P., Hanahan D., VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis. Cancer Cell 2002 1 2 193 202 2-s2.0-0036491615 10.1016/S1535-6108(02)00031-4 (Pubitemid 41039165)